| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 34,185 | 49,041 | ||
| Short-term investments | 109,441 | 109,046 | ||
| Accounts receivable | 1,629 | 1,869 | ||
| Prepaid expenses and other current assets | 3,962 | 4,665 | ||
| Total current assets | 149,217 | 164,621 | ||
| Property and equipment, net | 1,721 | 1,946 | ||
| Intangible assets, net | 474 | 510 | ||
| Goodwill | 949 | 949 | ||
| Restricted cash | 1,028 | 1,028 | ||
| Operating lease right-of-use asset | 4,814 | 5,947 | ||
| Other assets | 51 | 56 | ||
| Total assets | 158,254 | 175,057 | ||
| Accounts payable | 646 | 227 | ||
| Accrued liabilities | 12,408 | 11,503 | ||
| Operating lease liabilities - short term | 5,596 | 5,443 | ||
| Deferred revenue, current portion | 22,379 | 22,050 | ||
| Total current liabilities | 41,029 | 39,223 | ||
| Deferred revenue, net of current portion | 5,537 | 10,241 | ||
| Operating lease liabilities - long term | 0 | 1,442 | ||
| Other long term liabilities | 4,299 | 4,241 | ||
| Total liabilities | 50,865 | 55,147 | ||
| Convertible preferred stock | 0 | 0 | ||
| Common stock | 2 | 2 | ||
| Additional paid-in capital | 789,720 | 788,083 | ||
| Accumulated other comprehensive income | 104 | 33 | ||
| Accumulated deficit | -682,437 | -668,208 | ||
| Total stockholders' equity (deficit) | 107,389 | 119,910 | ||
| Total liabilities and stockholders' equity (deficit) | 158,254 | 175,057 | ||
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)